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Abstract
Background: Mesenchymal stem cells (MSCs) are multipotent cells residing in the connective tissue of many organs and
holding great potential for tissue repair. In culture, human MSCs (hMSCs) are capable of extensive proliferation without
showing chromosomal aberrations. Large numbers of hMSCs can thus be acquired from small samples of easily obtainable
tissues like fat and bone marrow. MSCs can contribute to regeneration indirectly by secretion of cytokines or directly by
differentiation into specialized cell types. The latter mechanism requires their long-term acceptance by the recipient.
Although MSCs do not elicit immune responses in vitro, animal studies have revealed that allogeneic and xenogeneic MSCs
are rejected.
Methodology/Principal Findings: We aim to overcome MSC immune rejection through permanent down-regulation of
major histocompatibility complex (MHC) class I proteins on the surface of these MHC class II-negative cells through the use
of viral immune evasion proteins. Transduction of hMSCs with a retroviral vector encoding the human cytomegalovirus
US11 protein resulted in strong inhibition of MHC class I surface expression. When transplanted into immunocompetent
mice, persistence of the US11-expressing and HLA-ABC-negative hMSCs at levels resembling those found in
immunodeficient (i.e., NOD/SCID) mice could be attained provided that recipients’ natural killer (NK) cells were depleted
prior to cell transplantation.
Conclusions/Significance: Our findings demonstrate the potential utility of herpesviral immunoevasins to prevent rejection
of xenogeneic MSCs. The observation that down-regulation of MHC class I surface expression renders hMSCs vulnerable to
NK cell recognition and cytolysis implies that multiple viral immune evasion proteins are likely required to make hMSCs non-
immunogenic and thereby universally transplantable.
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Introduction
Mesenchymal stem cells (MSCs) are multipotent cells present in
the stroma of most organs. Their isolation relies on adherence to
cell culture plastics. In culture, human MSCs (hMSCs) are capable
of extensive proliferation without giving rise to chromosomal
aberrations [1]. Large numbers of hMSCs can thus be obtained
from small samples of easily accessible tissues like fat and bone
marrow (BM).
MSCs are identified primarily on the basis of their ability to
differentiate under specific culture conditions into various
mesodermal cell types including osteoblasts, chondrocytes and
adipocytes. Since markers exclusively displayed on the surface of
MSCs have not been identified yet, these cells are phenotypically
characterized by a combination of several non-hematopoietic cell
surface markers [2].
Typically, cultured hMSCs express on their surface the major
histocompatibility complex (MHC) class I human leukocyte
antigens A, B, C (HLA-ABC) and HLA-G, but not HLA-E 3, 4
and our unpublished observations. Furthermore, hMSCs do not
display MHC class II (HLA-DR) proteins on their plasma
membrane. MHC class II molecules are present, however, in
intracellular reservoirs and can be recruited to the cell surface
through exposure to interferon gamma (IFN-c) [5,6].
Recently, cultured MSCs were shown to have pleiotropic
immunomodulatory properties in vitro including suppression of T
cell proliferation in response to alloantigens or mitogens [7,8],
inhibition of B cell proliferation and antibody production [9,10]
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hMSCs are not lysed by freshly isolated allogeneic natural killer
(NK) cells but are susceptible to the lytic activity of activated NK
cells [13,14]. In vivo, allogeneic MSCs were shown to prolong the
survival of skin allografts in baboons [7] and hMSCs ameliorated
experimental autoimmune encephalitis in mice [15]. In patients,
infusion of allogeneic hMSCs has been shown to mitigate acute
graft-versus-host disease to various degrees [16–18]. The reputa-
tion ‘‘non-immunogenic’’ that has been bestowed upon MSCs on
the basis of these findings, has been challenged by studies with
laboratory animals showing rejection of MSCs in allogeneic
transplantation settings. The therapeutic benefits that have been
observed after in vivo administration of MSCs are thus commonly
believed to result mainly or exclusively from paracrine effects
[reviewed in 19].
Repair of tissue damage that requires in situ differentiation of
MSCs into specialized cell types or their fusion with resident cells
has been attained only with autologous/syngeneic MSCs or in
immunocompromised recipients [20–25]. Similarly, successful use
of MSCs as vehicles for the delivery of therapeutics depends on
immunocompatible donor-recipient combinations [26,27].
The involvement of surface-displayed MHC class I molecules in
graft rejection and the mitigation of transplant immunogenicity
through interference with MHC class I protein recognition have
been well documented. Masking of MHC class I molecules by
specific antibodies enabled transplantation of human pancreatic
islands and liver cells in mice and of porcine neurons in rats
[28,29]. Moreover, neurons of MHC class I
2 transgenic mice
were not rejected in rats [30]. Along the same line, adipose tissue-
derived hMSCs that had lost MHC class I surface expression
during long-term culture, effectively contributed to skeletal muscle
repair in immunocompetent dystrophic mice [31]. Recently,
Zdoroveac and co-workers [32] demonstrated reduced immune
responses to carotid allografts genetically modified to decrease
surface levels of MHC class I antigens through an endoplasmic
reticulum-targeted MHC class I-specific intrabody.
Inhibition of MHC class I surface expression is a mechanism
evolved by viruses to prevent killing of their targets cells by the
hosts’ immune system [33,34]. Examples are herpesviruses that
encode so-called immune evasion proteins (also known as
immunoevasins), which specifically target different steps of the
MHC class I-mediated peptide presentation pathway to elude the
activity of CD8
+ T cells. Some of these proteins, like the bovine
herpesvirus type 1 (BHV-1) UL49.5 protein and the Epstein-Barr
virus (EBV) BNLF2a protein, are inhibitors of the transporter
associated with antigen processing (TAP), an essential component
of the MHC class I antigen presentation pathway [35–37]. Other
herpesviral proteins like the human cytomegalovirus (HCMV) US2
and US11 gene products, target MHC class I molecules for
destruction through dislocation of newly synthesized proteins into
to the cytosol where they are degraded by proteasomes [38,39].
Herpesviruses also evolved strategies to interfere with the
presentation of viral antigens to MHC class II-restricted CD4
+
T cells and to escape NK cell responses [reviewed in 40, 41].
In this study, we investigated whether immune rejection of
foreign cells could be prevented by controlled permanent down-
regulation of MHC class I surface expression. Using retroviral
vectors (RVs) encoding four different herpesviral immunoevasins,
we identified the US11 protein as a very effective inhibitor of
MHC class I surface display in hMSCs. The immunogenicity of
MHC class I
2 hMSCs should ideally have been tested in an
allogeneic recipient. This not being feasible, we resorted to the use
of mouse models to study the in vivo persistence of hMSCs
displaying normal or greatly reduced numbers of MHC class I
molecules at their plasma membrane. In this xenotransplantation
setting, we found US11-transduced hMSCs to be protected from
rejection in immunocompetent recipients, albeit only after
depletion of NK cells. This is, to our knowledge, the first in vivo
study demonstrating the utility of herpesviral immunoevasins to
modulate the immunogenicity of transplanted culture-expanded
primary human cells.
Results
Herpesviral immune evasion proteins greatly differ in
their ability to inhibit HLA-ABC expression on the surface
of hMSCs
Four different herpesviral immunoevasins were tested for their
ability to alter the expression of HLA-ABC on the surface of
hMSCs. To this end, hMSCs from a single donor (i.e. donor 1)
were stably transduced with bicistronic RVs coding for the
enhanced green fluorescent protein (eGFP) and for the product of
the BHV-1 UL49.5 gene (RV-UL49.5-eGFP), the EBV BNLF2a
gene (RV-BNLF2a-eGFP), the HCMV US2 gene (RV-US2-eGFP)
or the HCMV US11 gene (RV-US11-eGFP). Untransduced
hMSCs and cells transduced with an RV coding for eGFP only
(RV-eGFP) served as negative controls. Flow cytometric analysis
performed 5, 30 and 90 days after transduction revealed that a
large proportion of the cells in each of the transduced samples
expressed eGFP (Fig. 1A). The HLA-ABC levels on the plasma
membrane of the eGFP
+ cells, as determined by staining with
HLA-ABC-specific antibodies differed, however, depending on the
herpesviral gene present (Fig. 1A). Whereas untransduced and
RV-eGFP-transduced hMSCs expressed high levels of plasma
membrane-bound MHC class I molecules, HLA-ABC molecules
were barely detectable on the surface of cells transduced with RV-
US11-eGFP. A comparison of the HLA-ABC signal intensities
between the GFP
+ and GFP
2 (i.e. untransduced) cells in the RV-
US11-eGFP treated sample (Fig. 1B) showed that forced US11
expression causes a 46-fold reduction in HLA-ABC surface levels
(mean fluorescent activity [MFI] of 5 and 229, respectively).
Down-regulation of plasma membrane-bound HLA-ABC mole-
cules was also observed in hMSCs exposed to RV-US2-eGFP
albeit to a lesser extent (with a MFI ratio of untransduced versus
transduced cells of 5.2). In hMSCs transduced with the RVs
encoding the BNLF2a or UL49.5 protein, HLA-ABC surface
expression was reduced only marginally (for both vectors the MFI
ratios of untransduced versus transduced cells was 1.2).
The similar frequency of eGFP
+ cells and the similar average
intensity of the eGFP signal in the eGFP
+ cells in all RV-treated
samples suggest that hMSCs had been transduced with approx-
imately equal efficiency by the different RVs. Western blot analysis
of proteins extracted from hMSCs at 21 days after transduction
confirmed the presence of the UL49.5, BNLF2a, US2 and US11
proteins (Fig. 1C).
Transduction of hMSCs isolated from the BM of three
additional donors (i.e. donors 2, 3 and 4) with RV-US2-eGFP or
RV-US11-eGFP yielded very similar results as for donor 1 (data
presented in Fig. 2A and 2C). All cells with down-modulated
HLA-ABC surface expression were also eGFP
+. Furthermore,
transduction with the RVs did not affect plasma membrane levels
of the CD44 protein, a marker of hMSCs (Fig. 2B).
Persistence of herpesviral immune evasion proteins in
hMSCs does not compromise their replication capacity
hMSCs transduced to express either of the four herpesviral
immunoevasin genes were kept in culture for five additional passages.
At each passage, the number of cells was determined and cell
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ABC. Overall growth characteristics were not affected by the
expression of the herpesviral immunoevasin genes (Fig. 3).
During the entire period of analysis, the frequency of eGFP
+
cells, the average eGFP signal per eGFP
+ cell, as well as the cell
surface expression level of HLA-ABC remained constant (data not
shown).
IFN-c partially overrules US2- and US11-mediated down-
regulation of MHC class I surface expression and elevates
surface levels of MHC class II molecules
Previous studies have demonstrated that treatment of hMSCs
with IFN-c induces cell surface expression of MHC class II
molecules [5,6]. We confirmed this finding (Fig. 4) with untrans-
duced hMSCs and showed that the same applies to hMSCs
transduced with RV-US2-eGFP or RV-US11-eGFP. In all three
cell populations surface MHC class II levels were equally high
after incubation for 48 hours with 100 ng/ml of IFN-c. Surface
MHC class I expression after IFN-c treatment depended on the
levels of plasma membrane-bound MHC class I molecules prior to
cytokine stimulation, i.e. HLA-ABC surface expression in RV-
US2-eGFP-transduced hMSCs was similar to that in untrans-
duced cells not treated with IFN-c but it was only partially restored
in cells transduced with RV-US11-eGFP.
Persistence of HLA-ABC-negative hMSCs in
immunocompetent mice requires depletion of NK cells
The effect of MHC class I surface expression on the engraftment
of hMSCs in mice was addressed by comparing the persistence of
RV-US11-eGFP-transduced hMSCs (US11-hMSCs) with that of
unmodified cells after intrapinnal implantation into immunodefi-
cient or immunocompetent mice.
To allow quantification of the surviving donor cells, we used in
this study US11-hMSCs and control hMSCs that were endowed
with a recombinant LacZ gene by transduction with the self-
inactivating lentiviral vector LV.C-EF1a.cyt-bGal. The b-galac-
tosidase (b-gal) activity in treated ears was determined with the
Beta-Glo assay system. Validation of this assay system revealed a
linear correlation between b-gal activity (expressed in relative light
units [RLUs]) and the number of donor cells injected (Fig. 5A).
Figure 1. Different herpesviral immunoevasins inhibit MHC class I expression on hMSCs to a different extent. (A) Flow cytometric
analysis of culture-expanded (Ctrl) hMSCs and of hMSCs transduced with RVs coding for eGFP alone or for eGFP and either the BHV-1 UL49.5, EBV
BNLF2A, HCMV US2 or HCMV US11 protein. The data are from cells analyzed 30 days after transduction. Analysis of the hMSCs at 5 and 90 days post-
transduction yielded very similar results (data not shown). MFIs of the HLA-ABC signal of eGFP
- (untransduced [UT]) and eGFP
+ (transduced [T]) cell
populations in each sample and their ratio are given below the dot plots (B). (C) Western blot analysis of lysates from untransduced hMSCs (2) and of
hMSCs transduced with RV-BLF2A-eGFP, RV-UL49.5-eGFP, RV-US2-eGFP or RV-US11-eGFP (+). The specificity of the antibodies used is indicated at the
left. Numbers at the right represent molecular weights in kilodalton (kDa). The 26-kDa and 19.4-kDa protein species recognized by the US2-specific
antibodies correspond to N-glycosylated and non-glycosylated forms of the US2 protein, respectively.
doi:10.1371/journal.pone.0014493.g001
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control (i.e. HLA-ABC
+) hMSCs and US11-hMSCs was similar
during the first 14 days after implantation with a reduction in b-gal
activity to 52619 and 6564% of day 0 values, respectively
(Fig. 5B, top panel).
In the immunocompetent C57Bl mice, the decrease in the
number of unmodified (i.e. HLA-ABC
+) hMSCs was more rapid,
i.e. on average only about 10% of the input cells remained at two
weeks after transplantation (Fig. 5B, middle panel). This difference
in the rate of reduction in b-gal activity between the two mouse
Figure 2. US2 and US11 inhibit MHC class I surface expression in hMSCs of different donors. (A) Flow cytometric analysis of HLA-ABC
surface expression in hMSCs derived from the BM of three different donors. Gray lines represent untransduced hMSCs. Black lines correspond to
hMSCs transduced with RV-US2-eGFP (upper panels) or with RV-US11-eGFP (lower panels). The presented data are from cells analyzed 30 days after
transduction. (B) Flow cytometric analysis of CD44 surface expression in hMSCs of donor 4 at 30 days after transduction with RV-US2-eGFP (upper
panel) or RV-US11-eGFP (lower panel). Similar results were obtained with cells of all other donors (data not shown). (C) Comparison of down-
regulation of HLA-ABC surface expression by RV-US2-eGFP and RV-US11-eGFP. Shown are HLA-ABC MFI values of untransduced (gray bars) and
transduced (black bars) cells of single samples of culture-expanded hMSCs from 4 donors (marked D1 to D4; values derived from data presented in
Fig. 1 and 2). The differences in the average MFI ratio (calculated as in Fig. 1) between the hMSCs exposed to RV-US2-eGFP and those transduced with
RV-US11-eGFP is highly significant (*p=0.0005).
doi:10.1371/journal.pone.0014493.g002
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Interestingly, following implantation in immunocompetent recip-
ients the US11-hMSCs disappeared faster than the unmodified
hMSCs (Fig. 5B, middle panel).
Immunohistological analysis of pinnea at 3, 7 and 14 days after
implantation of unmodified hMSCs or US11-hMSCs revealed
little cell infiltration at day 3 but massive infiltration of
granulocytes and NK cells at day 7, regardless of the MHC class
I surface levels of the implanted cells (Fig. 6). At day 14 after
transplantation, only few granulocytes and NK cells were detected
in the pinnea (Fig. 6A, 6B and 6D). The number of infiltrating
CD8
+ cells was, at all time points significantly higher in pinnea
implanted with unmodified hMSCs than in those injected with
US11-hMSCs (Fig. 6D).
To visualize NK cells, consecutive tissue sections were stained
with either anti-NKp46, anti-Ly49G2 or anti-NK1.1 antibodies.
Although NK.1.1
+CD3
2 and NK1.1
+CD3
+ cells were identified
by flow cytometry among peripheral blood mononuclear cells
(PBMCs) of C57Bl mice (Fig. 7), we could not detect NK1.1
+ cells
in sections of pinnea or control tissues (spleen and lymph nodes,
data not shown). Accordingly, in Fig. 6 sections stained with the
NKp46-specific antibody are presented. Similar frequencies and
distributions of positive cells were found in the sections stained
with the anti-Ly49G2 antibody (no statistical significant difference,
data not shown). Ly49G2 is present on the surface of both NK and
NK T cells, in contrast to the NKp46 protein, whose surface
expression is essentially restricted to NK cells. Our finding may
thus indicate the absence of substantial numbers of NK T cells in
the vicinity of the grafted cells.
The knowledge that lack of classical MHC class I surface
molecules can render cells susceptible to NK cell-mediated lysis
[42], and the evident infiltration of NK cells into the implantation
site, led to the proposition that NK cells are involvement in the
early rejection of US11-hMSCs in C57Bl mice.
Indeed, C57Bl recipient mice depleted of NK cells through
repeatedly administration of NK1.1-specific antibodies (Fig. 7)
maintained US11-hMSCs implants at levels similar to those in
NOD/SCID mice, which naturally display low NK cell activity
(Fig. 5B, lower panel). NK cell depletion did not significantly affect
the rate of decline of unmodified hMSCs in C57Bl mice. The
difference in the rejection kinetics of US11-hMSCs between
C57Bl mice with and without NK cells signifies that US11-hMSCs
can trigger NK cell activation in vivo and serve as targets for their
cytolytic activity.
Discussion
Modulation of immunogenicity using viral immune evasion
strategies has become a field of active research over the past
decade. In vitro studies conducted primarily with establish cell lines
revealed efficient inhibition of MHC class I/II surface expression
after transduction with viral vectors encoding EBV immunoeva-
Figure 3. Herpesviral immunoevasins do not compromise the
replication rate of hMSCs in culture. hMSCs were transduced at
passage number 8 with bicistronic RVs encoding eGFP and a herpesviral
immunoevasin and kept in culture for 7 additional passages. Lines
represent untransduced hMSCs (%) and cells transduced with RV-
UL49.5-eGFP (¤), RV-BNLF2A-eGFP (m), RV-US2-eGFP (&) or RV-US11-
eGFP (N) during 5 passages.
doi:10.1371/journal.pone.0014493.g003
Figure 4. IFN-c modulates expression of MHC class I and class II molecules on US2- and US11-transduced hMSCs. Flow cytometric
analysis of the expression of MHC class I (HLA-ABC; upper panels) or MHC class II (HLA-DR; lower panels) proteins on the surface of untransduced
hMSCs (Ctrl) and of cells transduced with RV-US2-eGFP (US2) or with RV-US11-eGFP (US11). The cells were (+ IFN-c) or were not (- IFN-c) incubated for
48 hours with 100 ng/ml IFN-c prior to flow cytometry. The US11- and US2-transduced hMSCs used for this experiment, were sorted on the basis of
eGFP expression.
doi:10.1371/journal.pone.0014493.g004
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previously reported to interfere with the MHC class I antigen-
presenting pathway, only the HCMV US11 protein strongly
downregulates MHC class I expression on the surface of culture-
expanded primary hMSCs. The HCMV US2 protein, which like
the US11 protein, dislocates class I heavy chain molecules into the
cytosol for subsequent degradation by proteasomes [39], was less
effective in the hMSCs. Using adenoviral vectors, Rehm et al. [43]
found that in primary human dendritic cells surface MHC class I
expression was also suppressed much more efficiently by the US11
protein as compared to the US2 protein while in the human
astrocytoma cell line U373 MG both immunoevasins were highly
effective.Comparisonofthe amounts oftheUS11 and US2proteins
in the two cell types made the authors conclude that the differential
effects of these two immunoevasins on the dendritic cells are not
caused by the differences in their steady-state levels. Rather, studies
with U373 MG cells expressing different murine class I heavy chain
proteins [44] and J26 cells (i.e. human B2M-transduced murine
fibroblasts) expressing distinct human HLA-ABC allomorphs
[45,46] revealed that US2- and US11-mediated down-regulation
of MHC class I surface expression in these cell types is haplotype-
specific. Notably, in our study, hMSCs derived from BM of four
donors showed a very similar US2- and US11-dependent decrease
in MHC class I surface expression.
The observed differences in the extent to which US2 and US11
inhibit expression of HLA-ABC on the surface of hMSCs may
relate to the fact that these immunoevasins depend on distinct
cellular proteins for their activity, which may be differently
regulated in hMSCs. For example, US11-mediated degradation of
MHC class I molecules requires Derlin-1 while the activity of US2
is Derlin-1-independent [47,48]. Also, ubiquitination of MHC
class I heavy chains is essential for their dislocation into the cytosol
by US2 but not by US11 [49].
Whatever the underlying cause, the observed difference
between distinct herpesviral immune evasion proteins in their
capacity to suppress MHC class I expression on the surface of
hMSCs argues for the screening of different immunoevasins for
each specific target cell type, donor and application.
The utility of a herpesviral immunoevasin to inhibit hMSC
rejection has been demonstrated here in a xenotransplantation
model. Our results show that permanent interference with surface
expression of MHC class I molecules with the aid of the US11
protein facilitates maintenance of the grafted cells in NK cell-
depleted immunocompetent mice at levels similar to those
obtained in immunodeficient recipients. The rapid decrease of
the b-gal activity in the ears of immunocompetent mice following
intrapinnal transplantation of LacZ-transduced US11-hMSCs, and
its prevention by NK cell depletion points to NK cell-mediated
rejection of the MHC class I
2 donor cells in this animal model.
Figure 5. Engraftment of hMSCs with modulated surface MHC
class I expression in immunodeficient and immunocompetent
mice. (A) Correlation between donor cell number and b-gal activity
(expressed in RLUs) in the ears of mice following intrapinnal injection of
LacZ-expressing hMSCs. The ears of the treated mice (four mice for each
cell dose) were excised 5 minutes after cell injection and processed as
described in the Materials and Methods section. Each dot represents a
single ear. (B) Engraftment of hMSCs in immunodeficient mice (upper
graph), immunocompetent mice (middle graph) and immunocompe-
tent mice depleted of NK cells (lower graph). Indicated on the vertical
axis is the average b-gal activity in whole ears of mice sacrificed at the
specified time points after the injection of cell or PBS as compared to
that of mice killed 5 minutes after the injection of cells from the same
batch (time 0; 100%). The graphs show time-related changes in relative
b-gal activity for sorted US11-hMSCs (solid line andN) and for untreated
hMSCs (dotted line and ¤) in NOD/SCID mice, C57Bl mice and NK cell-
depleted C57Bl mice. Background b-gal activity values were derived
from mice whose pinnae were injected with vehicle only (broken line
and m). Individual data points represent the average (6 SD) relative b-
gal activity of 3 to 14 animals and have been derived from 2 to 4
independent experiments. Statistical analysis was performed at each
time point and through all three graphs for pairs of data points derived
from all mice in a particular experimental group. Significant difference
(p,0.002) between data points were marked s1 and s2 while non-
significant differences (p.0.5) between data pairs are indicated by n1
and n2.
doi:10.1371/journal.pone.0014493.g005
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as observed in this study (Fig. 6), differs from the acute (within
24 hours) infiltration of innate immune cells into solid organ
implants or into sites of cutaneous inflammation [50,51]. We
propose that this delay (few cells at day 3 post implantation and
high numbers at day 7) is caused by the implanted hMSCs and in
particular their ability to modulate the cytokine milieu near the site
of cell injection. Implantation of hMSCs into ischemic kidneys
resulted, after 24 hours, in an increase in anti-inflammatory
cytokine (i.e IL-10) gene expression and in a decrease in mRNA
levels for the pro-inflammatory cytokines IFN-c, TNF-a and IL-1b
[52]. Interestingly, in MSC-treated infarcted rat hearts pro/anti-
inflammatory cytokine gene expression ratios increased between
24 hours and 2 weeks after MSC implantation [53]. This
phenomenon may well explain the delayed leukocyte infiltration
following hMSC implantation in our experiments.
The elimination of MHC class I
2 hMSCs by NK cells would be
consistent with the ‘‘missing self’’ hypothesis [54] and the reported
prominent role of NK cells in xenograft rejection [55]. Our
findings, however, do not concur with other studies reporting
engraftment of MHC class I
2 cells in xenogeneic or allogeneic
recipients without active suppression of NK cell activity [28–
32,56]. In view of the different strategies used in these studies (i.e.
antibody-mediated masking, B2M gene knockout, long-term
culture, proteins encoded by the adenoviral early region 3) it is
tempting to speculate that the observed differences result from
qualitative and quantitative differences in residual HLA antigen
expression on the surface of the donor cells. Also the donor cell
type and the specific NK cell repertoire of the recipients may have
affected the outcome of the experiments.
It is worth noting that hMSCs do not persist at constant high
levels in immunodeficient mice. A time-related decline in the
number of implanted hMSCs, as observed in this study, has also
been documented in other xenograft models that enabled
quantification of the implanted cells [57–59].
This disappearance of xenografted cells in the absence of
adaptive immune responses is poorly understood. Involvement of
host innate immune cells has been proposed but, so far, not proven
Figure 6. Infiltration of recipient’s immune cells in the vicinity of the hMSC-implants. Immunohistological and histochemical analysis of
frozen tissue section. (A and B) Pinnea excised 3, 7 and 14 days after implantation of LacZ-transduced hMSCs (A) or LacZ-transduced US11-hMSCs (B).
Implanted hMSCs are visualized in the pinnea by X-gal (blue) staining. DAB staining was used to identify granulocytes (endogenous peroxidase) and
CD8
+ cells. The granulocytes are recognized by the intracellular localization of the brown precipitate while the CD8
+ cells (arrows) are predominantly
showing staining of the plasma membrane. The anti-NKp46 antibody was used to identify NK cells (red, cell membrane staining) and nuclei were
stained with Hoechst 33342 (blue). (C) Control tissues (pinna and spleen). (D) CD8
+ and NK cell counts in pinnea transplanted with untreated hMSCs
(black bars) or US11-hMSCs (gray bars). The data represent averages 6 SD of CD8
+ and NKp46
+ cells present in 9 different tissue sections (3 pinnea
per experimental group and 3 sections with a mutual distance of 32 mm per pinna). *p,0.05.
doi:10.1371/journal.pone.0014493.g006
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an intrinsic property of implanted ‘‘free cells’’ that have been
deposited in an unfavorable microenvironment. This perception is
supported by results of Eliopoulos and colleagues, showing a limited
persistence of murine MSCs following subcutaneous implantation
into syngeneic recipients. Long-term survival of the implanted cells
was significantly improved by embedding the MSCs into a matrix
prior to implantation, emphasizing that the subcutis represents a
suboptimal milieu for MSC transplantation [27,61]. The observa-
tion that US11-hMSC numbers diminish in NK cell-depleted
C57Bl mice with similar kinetics as in NOD/SCID mice suggests
that in vivo these MHC-class I
2 cells do not activate any other
immuneeffectorcellsthantheNKcells.Thisisespeciallyinteresting
in view of our finding that like in US11-transduced tumor cell lines
[62], in vitro exposure of US11-hMSCs to IFN-c alleviates the effect
of the immunoevasin and upregulates cell surface MHC class II
protein expression. Apparently, such upregulation does not occur to
any significant extent in vivo. Rather, a strong inhibition of the
expression of genes encoding pro-inflammatory cytokines including
IFN-c was recorded in injured kidney tissue of rats following
administration of MSCs [52]. If the interpretation of our results is
correct, endowing hMSCs with the US11 protein and an
immunoevasin that efficiently blocks NK cell-mediated cytolysis
would result in completely non-immunogenic hMSCs for universal
application.
Protection against the adverse effects of NK cells could be
provided by viruses as well. Human and murine cytomegalovirus,
for example, encode MHC class I-like molecules that can serve as
decoys for NK cells [63,64]. Other strategies to inhibit NK cell-
mediated donor cell destruction including interference with their
activation receptors and modulation of certain cytokine-dependent
signaling pathways have also been described [reviewed in 65].
In conclusion, we have demonstrated the potency of an HCMV
immunoevasin to completely downregulate MHC class I expres-
sion on the surface of culture-expanded primary hMSCs.
Following subcutaneous implantation into immunocompetent
mice, the MHC class I
- hMSCs underwent fast rejection that
was attributed to NK cell activity. However, in immunocompetent
mice depleted of NK cells, US11-hMSCs gradually disappeared at
a rate similar to that in immunodeficient hosts. Admittedly it is by
no means certain that the xenograft model used in this study is
fully predictable for the human situation, but our results show at
least the expediency of viral immunoevasins in hMSCs and
provide a rationale for transferring additional immunoevasin genes
to generate universal donor cells.
Materials and Methods
Isolation and culture of BM-derived hMSCs
hMSCs were obtained from BM samples of four donors (2 males
and 2 females, age range 38 to 72 years) collected during
orthopedic surgery with a written informed consent and according
to the guidelines of the Leiden University Medical Center (LUMC,
Leiden, the Netherlands). hMSCs were isolated from the BM
samples as described previously [3]. Briefly, the cells were seeded
in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen-
Gibco, Breda, the Netherlands) containing 100 U/ml penicillin
(Invitrogen-Gibco), 100 mg/ml streptomycin (Invitrogen-Gibco)
and 10% fetal bovine serum (FBS; Invitrogen-Gibco) in plastic cell
culture flasks (Greiner Bio-One, Alphen aan den Rijn, the
Netherlands) and incubated for 48 hours at 37uC in humidified
air and 10% CO2. Thereafter, the non-attached cells were
removed and the adherent cells were grown to 70% confluency
before transfer for further expansion [3]. At passage number 2,
aliquots of 2610
5 cells were cryopreserved. hMSC expansion was
performed in culture medium supplemented with 0.5 ng/ml basic
fibroblast growth factor (Sigma-Aldrich, St. Louis, MO). Cell
replication was monitored for up to 15 passages from cultures
Figure 7. NK cell levels in C57Bl mice treated with NK1.1-specific MAbs. Flow cytometric analysis of PBMCs of a representative mouse
stained with antibodies directed to murine CD45, CD3 and NK1.1. The upper panels show data of peripheral blood taken before treatment with
NK1.1-specific MAbs. The lower panels are derived from a peripheral blood sample taken 7 days after intraperitoneal injection of 100 mg anti-NK1.1
antibodies. Cells stained with isotype-matched control antibodies are depicted in the left column. In the right column only CD45
+ cells that were
gated in R1 (middle column) have been analyzed for surface expression of NK1.1 (gate R2) and CD3 (gate R3). All peripheral blood samples of mice
treated with NK1.1-specific MAbs showed similar low levels of NK1.1
+ CD3
2 cells.
doi:10.1371/journal.pone.0014493.g007
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4/cm
2 of freshly thawed cells in 25-cm
2
cell culture flasks (Greiner bio-One, Frickenhousen, Germany).
After reaching 70–80% confluency, the total number of cells in
each culture was determined and a fraction of them was re-plated
for a next passage under the same conditions as before.
The characterization of the cultured hMSCs by immunophe-
notyping and in vitro differentiation assays has been reported before
[3,66].
Viral vectors and hMSC transduction
The coding sequences of the BHV-1 UL49.5, EBV BNLF2a and
HCMV US2 and US11 genes were amplified from viral DNA by
polymerase chain reaction (PCR). The resulting PCR fragments
were inserted in the gammaretroviral vector shuttle plasmid
pLZRS-IRES-GFP upstream of the internal ribosome entry site as
described previously [35,36,67,68]. Recombinant retroviruses
directing the synthesis of eGFP and either of the four herpesviral
immunoevasins were prepared using the Phoenix amphotropic
packaging system as described previously [69].
Culture-expanded hMSCs (passages 4 to 8) were transduced
with the recombinant retroviruses in RetroNectin (Takara Bio
Europe, Saint-Germain-en-Laye, France)-coated dishes. Two or
three rounds of transduction were performed at 24-hour intervals.
For in vivo studies, RV-transduced hMSCs were sorted on the
basis of eGFP levels using a FACSDiva (Becton Dickinson [BD],
Breda, the Netherlands). The eGFP
+ MHC class I
- cells as well as
untransduced hMSCs from the same batch of cells were then
exposed to the vesicular stomatitis virus G protein-pseudotyped
self-inactivating lentiviral vector LV.C-EF1a.cyt-bGal [70], en-
coding Escherichia coli b-gal. The cells were incubated for 4 hours
with 2 HeLa cell-transducing units of the LV.C-EF1a.cyt-bGal
vector/hMSC in DMEM containing 10% FBS and 8 mg/ml
hexadimethrine bromide (polybrene; Sigma-Aldrich) at 37uC [71].
Transduction efficiencies were determined 14 days later by
staining the cells with 2 mM 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (Sigma-Aldrich) as described previously [72].
Typically, more than 90% of the LV.C-EF1a.cyt-bGal-transduced
hMSCs were b-gal
+ at this time point as well as after multiple ex
vivo cell doublings.
Antibodies and flow cytometry
Flow cytometric analyses were performed with a FACSort (BD)
using the following murine monoclonal antibodies (MAbs):
phycoerythrin (PE)-conjugated anti-human CD44 (clone G44-26;
BD), PE-conjugated anti-HLA-ABC complex (clone W6/32; Dako
Netherlands, Heverlee, Belgium) and PE-conjugated anti-HLA-DR
(clone L243; BD). NK cells in the peripheral blood samples of the
recipient mice were detected with PE-conjugated anti-mouse
NK1.1 (clone PK126; BD), fluorescein isothiocyanate (FITC)-
conjugated anti-mouse CD3 (clone 17A2; BD) and peridinin-
chlorophyll-protein-complex (PerCP)-conjugated anti-mouse CD45
(clone 30-F11; BD) MAbs. Control MAbs (mouse IgGs conjugated
with FITC, PE or PerCP; BD) were used for gate positioning.
Immunoblotting
RV-transduced hMSCs were lysed in 0.5% Nonidet P-40,
50 mM Tris-HCl (pH 7.5), 5 mM MgCl2,1 0 mM leupeptin
(Sigma-Aldrich) and 1 mM 4-(2-aminoethyl) benzenesulfonyl
fluoride (Sigma-Aldrich). The proteins in the lysates were
separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and transferred to polyvinylidene fluoride membranes
(Hybond-P; GE Healthcare Europe, Diegem, Belgium). The
resulting blots were incubated with the rat monoclonal antibody
MVH 5B9 for the detection of BNLFA2a [73], a rabbit polyclonal
antiserum directed against amino acids 22 through 51 of the BHV-
1 UL49.5 protein [74] or a rabbit polyclonal antiserum specific for
the N-terminus of the HCMV US2 protein (amino acids 24
through 41; [68]). For the detection of the HCMV US11 protein,
a rabbit antiserum directed against the N-terminus of the protein
was used (amino acids 21 through 38; [67]). Horseradish
peroxidase-conjugated secondary antibodies (Dako Netherlands)
and Amersham ECL Plus Western Blotting Detection Reagents
(GE Healthcare Europe) were used to visualize bound primary
antibodies.
Mice and the xenotransplantation model
NOD/LtSz-scid/scid/J (NOD/SCID) mice were bred in the
animal facilities of the LUMC from breeding pairs purchased from
Jackson Laboratories (Bar Harbor, ME). Animals were housed under
specific pathogen-free conditions as described previously [75].
C57Bl/6J (H-2
b) (C57Bl) mice were purchased from Harlan
(Venray, the Netherlands). Male and female mice 8–12 weeks old
were used. The animal room was on a 12:12-hours light-dark cycle
and kept at 22uC. Standard laboratory chow and sterile water
were provided ad libitum. All experiments were performed
according to a study protocol approved by the Animal Ethics
Committee of the LUMC.
hMSC engraftment was studied by subcutaneous injection of
3–5610
5 LacZ-tagged cells in a total volume of 20 ml phosphate-
buffered saline (PBS) into the pinna of one of the ears of either
NOD/SCID mice, C57Bl mice or C57Bl mice that had been
depleted of NK cells by intraperitoneal injection of 100 mg per
treatment of sodium azide-free affinity purified anti-mouse NK1.1
MAbs (clone PK136; BD or BioLegend, San Diego, CA). Anti-
body administration was initiated 24 hours prior to hMSC
implantation and repeated once a week thereafter. The level of
NK cells in these mice was determined by flow cytometric analysis
of PBMCs that were sampled prior to each antibody injection and
before sacrificing the mice. PBMCs of untreated mice served to
derive control values.
The relative amount of LacZ-expressing human cells in the ears of
the treated mice was determined with the Beta-Glo assay system
(Promega Corporation, Madison, WI) [76,77]. At different time
points after hMSC implantation, mice were sacrificed, the whole
treated ear was dissected, snap-frozen in liquid nitrogen and stored
at 280uC until processing. Each ear was homogenized in 1 ml of
homogenization buffer (10 mM KCl, 1.5 mM MgCl2 and 10 mM
Tris-HCl [pH 7.4]) on ice as described [78]. The homogenate was
clearedbycentrifugation for10 minutes at 20,8006Ga n d4 uC. The
supernatants were analyzed for b-gal activity according to the
protocol provided by the manufacturer of the Beta-Glo assay
system. Chemoluminescence was measured using a Wallace 1420
VICTOR 3 multilabel plate reader (PerkinElmer Nederland,
Groningen, the Netherlands). b-gal activity was expressed in RLUs.
Serial dilutions of each supernatant were analyzed and plotted
against RLUs. RLUs of different samples were compared at a
dilution positioned in the linear range of the dose-response curve.
For each experimental group, the b-gal activity at each time
point is presented as a percentage of the average b-gal activity
detected in the ears of mice immediately (i.e. within 5 minutes)
after cell injection (time 0; 100%), allowing a direct comparison of
all experimental groups in the four in vivo experiments that were
performed.
Immunohistology of pinnea
C57Bl mice were injected as above with LacZ-tagged hMSCs.
Three mice per treated group were sacrificed at 3, 7 and 14 days
after cell injection. Ears were dissected and frozen by liquid
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processing. Three consecutive transversal cross-sections of 8 mm
were placed on SuperFrost Plus glass slides (Menzel-Gla ¨ser,
Braunschweig, Germany) and stored at 220uC.
The first slide of each pinna was processed for X-gal staining as
described before [70]. Sections were counterstained with nuclear
fast red and saffron according to standard procedures and
mounted in Entellan mounting medium (Merck, Schiphol-Rijk,
the Netherlands).
Immunostaining of the tissues was performed with antibodies
specific for CD8 and NK cells. The sections were fixed with ice-
cold acetone (Mallinckrodt Baker, Deventer, the Netherlands) for
5 minutes at 4uC, air-dried and washed once for 5 minutes with
PBS. A peroxidase blocking step was performed by incubating the
sections for 10 minutes with 0.3% H2O2 in H2O followed by two
PBS washes for 5 minutes each. Sections were then treated with
the M.O.M. Immunodetection Kit Basic (Vector Laboratories,
Burlington, CA) accordingly to the manufacturer’s specifications.
For the staining of CD8
+ cells, biotinylated rat anti-mouse CD8a
MAb (Biolegend; clone 53-6.7; IgG2a; 1:250) was added for
overnight incubation at 4uC. As isotype control antibody we used
biotin-conjugated rat IgG2a MAb (Biolegend; clone RTK2758;
1:200). Antibodies were removed by washing twice with PBS for 5
minutes. The Vectastain Elite ABC Kit (Vector Laboratories) was
then applied according to manufacturer’s specifications. Bound
antibody complexes were visualized with 3,39-diaminobenzidine
(DAB, Sigma-Aldrich). Sections treated with DAB only were used
to stain granulocytes. Finally, the sections were counter-stained
with hematoxylin, dehydrated and mounted in Entellan mounting
medium. Images were captured with a ColorView IIIu camera
(Olympus Nederland, Zouterwoude, the Netherlands) mounted on
a Leitz Wetzlar Diaplan microscope (Germany) and processed
with Cell
B imaging software (Olympus).
Three antibodies were used for the detection of NK cells: the
biotinylated mouse anti-mouse NK1.1 MAb (Biolegend; clone
PK136; IgG2a; 1:10), the goat anti-mouse NKp46 polyclonal
antibody (R&D Systems Europe, Abingdon, United Kingdom;
IgG; 1:100) and the rat anti-mouse Ly49G2 MAb (BD; clone
4D11; IgG2a; 1:20). The corresponding isotype controls were a
mouse IgG2a MAb (Biolegend; clone MOPC-173; 1:200), goat
serum (1:10) and the previously mentioned biotin-conjugated rat
IgG2a MAb (1:200). Tissues were incubated overnight at 4uC with
the first antibody. After washing with PBS, tissues were exposed to
a 2.5-hour incubation with streptavidine-conjugated Qdot 655
(Invitrogen-Molecular Probes; 1:200), Alexa 594-coupled donkey
anti-goat IgG (Invitrogen-Molecular Probes; 1:800) or Alexa 488-
conjugated donkey anti-rat IgG (Invitrogen-Molecular Probes;
1:400), respectively. PBS-washed sections were then incubated
with Hoechst 33342 (1:1000 in PBS, Invitrogen-Molecular Probes)
for 10 minutes, washed thoroughly (3–4 times) with PBS and
mounted in Vectashieled. Microscopic analysis was performed on
using Leica DM5500 B fluorescence microscope (Leica Micro-
systems, Rijswijk, the Netherlands). Images were captured with a
cool SNAP K4 CCD camera (Photometrics, Tucscon, AZ) and
archived with home-made software.
Statistics
Data were analyzed with the one-way analysis of variance.
Results are expressed as the mean 6 standard deviation (SD). A
p-value ,0.05 was considered significant.
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